Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS PEDIATRIC (CM) – erenumab in children and adolescents with chronic migraine
2017-002399-23Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine and migraine comparing erenumab with placebo (2 arms). Primary endpoint: Change in monthly migraine days. Started Mar 2019; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migrainemigraine
Beyond the preview
Go deeper on 2017-002399-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002399-23.